Table 1

Studies¹	Target	Condition	Interventions	Phase
Temsirolimus
NCT00926107	Ovarian cancer	Recurrent	Temsirolimus	Phase II
NCT00429793	Ovarian cancer Fallopian tube cancer Primary peritoneal cancer	Recurrent	Temsirolimus	Phase II
NCT01196429 GOG0268	Clear cell ovarian cancer (Stage III-IV)	First-line therapy	Temsirolimus plus carboplatin/paclitaxel flowed by temsirolimus consolidation	Phase II
NCT01460979	Ovarian cancer Endometrial cancer	Recurrent	Temsirolimus	Phase II
NCT01010126	Solid tumors	Advanced or recurrent	Temsirolimus plus bevacizumab	Phase II
NCT00982631	Ovarian cancer Breast cancer Endometrial cancer	Advanced or recurrent	Temsirolimus plus PLD	Phase I
NCT00408655	Solid tumors	Advanced	Temsirolimus plus carboplatin/paclitaxel	Phase I
NCT00523432	Gynecologic malignancies	Recurrent	Temsirolimus plus topotecan	Phase I
NCT00703170	Solid tumors	Recurrent	Temsirolimus plus PLD	Phase I
NCT01155258	Solid tumors	Advanced	Temsirolimus plus vinorelbine ditartrate	Phase I
NCT00703625	Solid tumors	Recurrent	Temsirolimus plus docetaxel	Phase I
NCT01065662	Gynecologic malignancies	Recurrent	Temsirolimus plus cediranib	Phase I
Everolimus
NCT01149434	Solid tumors	Advanced	JI-101 vs JI-101 plus everolimus	Phase I/II
NCT01031381	Ovarian cancer Fallopian tube cancer Primary peritoneal cancer	Recurrent	Everolimus plus bevacizumab	Phase II
NCT00886691	Ovarian cancer Fallopian Tube Cancer Primary Peritoneal Cancer	Recurrent	Bevacizumab vs bevacizumab plus everolimus	Phase II
JGOG3021²	Clear cell ovarian cancer	Recurrent	Everolimus	Phase II
Ridaforolimus
NCT01256268	Ovarian cancer Endometrial cancer	Recurrent or advanced	Ridaforolimus plus carboplatin/paclitaxel	Phase I
NCT01295632	Solid tumors	Advanced	Ridaforolimus	Phase I

¹ClinicalTrials.gov identifier. ²This study will be initiated from September 2014. PLD; pegylated liposomal doxorubicin hydrochloride, GOG; Gynecologic Oncology Group, JGOG; Japanese Gynecologic Oncology Group.

Table 1: Summary of mTORC1 inhibitors in clinical trials.